Superworth

Alnylam Pharmaceuticals EV/EBIT ALNY

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Nov 3, 2026
19.2×
2-year median
80.7×
Against its 2-year history
0th
percentile: 0 is its lowest day, 100 its highest
2-year range
19.2× to 357×
Peer median
23.5×

Alnylam Pharmaceuticals' EV/EBIT is 19.2× as of Nov 3, 2026.

That is below its 2-year median of 80.7×, lower than on 100% of days in the last 2 years.

Over that time it ranged from 19.2× in Nov 2026 to 357× in Oct 2024.

The median for 10 biotech stocks of a similar size is 23.5×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.2×19.2×194×
2025195×193×223×
2024344×296×357×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Where Alnylam Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.